aspirin has been researched along with hirudin in 119 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (5.04) | 18.7374 |
| 1990's | 46 (38.66) | 18.2507 |
| 2000's | 40 (33.61) | 29.6817 |
| 2010's | 23 (19.33) | 24.3611 |
| 2020's | 4 (3.36) | 2.80 |
| Authors | Studies |
|---|---|
| Kinlough-Rathbone, RL; Mustard, JF; Packham, MA; Perry, DW | 1 |
| Hoak, JC; Wu, KK | 1 |
| Hornstra, G; ten Hoor, F | 1 |
| Pearson, JD; Royston, BD; Royston, D | 1 |
| Théroux, P | 1 |
| Collins, L; George, D; Johnstone, MT; Loscalzo, J; Moore, RT; Rabbani, LE; Rudd, MA | 1 |
| Chen, JH; Karlberg, KE; Sylvén, C | 1 |
| Eschenfelder, V; Rübsamen, K | 1 |
| Badimon, L; Chesebro, JH; Fuster, V; Heras, M; Lam, JY; Steele, PM; Webster, MW | 1 |
| Breddin, HK; Krupinski, K | 1 |
| Abendschein, DR; Haskel, EJ; Prager, NA; Sobel, BE | 1 |
| Ma, X | 1 |
| Aglietta, M; Breviario, F; Bussolino, F; Dejana, E; Mantovani, A; Tetta, C | 1 |
| Kunz, F; Zwierzina, WD | 1 |
| Baldini, MG; Hara, Y; Steiner, M | 1 |
| Côté, YP; Feinstein, MB; Lau, LF; Pumiglia, K | 1 |
| Belcher, PR; Drossos, GE; Evans, RD; Menys, VC; Noble, MI; Pillai, R; Westaby, S | 1 |
| Cannon, CP; Fuchs, J | 1 |
| Buchwald, AB; Ebbecke, M; Lüders, S; Munz, DL; Nebendahl, K; Sandrock, D; Unterberg, C; Wiegand, V | 1 |
| Bonan, R; Lespérance, J; Pérez-Villa, F; Shabani, F; Théroux, P; Waters, D | 1 |
| Lee, LV | 1 |
| Alving, BM; Barr, CF; Gomez, ER; Hamelink, JK; Jackson, MR; Reid, TJ; Tang, DB | 1 |
| Li, ZY; Lian, EC; Yu, TF | 1 |
| Antman, EM | 1 |
| Alexandre, A; Cavallini, L; Doni, MG | 1 |
| Lumley, P; Sullivan, AT; White, BP | 1 |
| Anderson, JL; Becker, RC; Cannon, CP; Gibson, RS; Haugland, JM; Henry, TD; Kleiman, NS; McCabe, CH; Mueller, HS; Schweiger, MJ | 1 |
| Menys, VC | 1 |
| Beretz, A; Cazenave, JP; Freund, M; Gachet, C; Mantz, F; Meyer, L; Mulvihill, J; Nicolini, P | 1 |
| Dawson, A; Eisner, J; Findlen, K; Fox, I; Hanson, D; Levin, E; Loynds, P; Mant, T; Maraganore, J; Wagner, J | 1 |
| Adelman, B; Braunwald, E; Cannon, CP; Eddings, K; Fox, I; George, D; Loscalzo, J; Maraganore, JM; McAllister, A; Selwyn, AP | 1 |
| Abendschein, DR; Prager, NA; Sobel, BE; Torr-Brown, SR | 1 |
| Schächinger, V; Zeiher, AM | 1 |
| Bosma, AH; Hertzberger, DP; Kingma, JH; Laarman, GJ; Lok, DJ; Luz, CM; Molhoek, GP; Takens, LH; Van den Bos, AA; Zijnen, P | 1 |
| Druker, BJ; Handa, M; Ikeda, Y; Miyakawa, Y; Miyazaki, H; Oda, A; Ohashi, H | 1 |
| Hirsh, J; Turpie, AG; Weitz, JI | 1 |
| Chesebro, JH; Fuster, V; Grill, DE; Heras, M; Holmes, DR; Mruk, JS; Webster, MW; Zoldhelyi, P | 1 |
| Husted, SE; Kristensen, SD; Ravn, HB; Vissinger, H | 1 |
| Meyer, BJ | 1 |
| Adelman, B; Adgey, AA; Aylward, PE; Brown, MA; Collins, R; French, JK; Frey, MJ; Hillis, WS; Maraganore, J; Nair, R; Shalev, Y; White, HD | 1 |
| Bentley, R; Bostwick, JS; Dunwiddie, CT; Kasiewski, CJ; Leadley, RJ; McVey, MJ; Perrone, MH; White, FJ | 1 |
| Badimon, JJ; Badimon, L; Chesebro, JH; Fallon, JT; Fuster, V; Meyer, BJ | 1 |
| Dickneite, G; Friesen, HJ; Nicolay, U; Reers, M | 1 |
| Anand, SS; Flather, M; Pogue, J; Weitz, JI; Yusuf, S | 1 |
| Aylward, P; Ellis, CJ; French, JK; White, HD | 1 |
| Topol, EJ | 1 |
| Edwards, N; Fox, SC; Henderson, RA; Heptinstall, S; Pascoe, J; Sanderson, HM; White, A | 1 |
| Kambayashi, J; Lockyer, S | 1 |
| Honye, J; Kanmatsuse, K; Saito, S | 1 |
| Turpie, AG | 1 |
| Anand, SS | 1 |
| Yusuf, S | 1 |
| Ankri, A; Choussat, R; Collet, JP; Drobinski, G; Lison, L; Montalescot, G; Perlemuter, K; Philippe, F; Thomas, D; Vicaut, E | 1 |
| Chauhan, A; More, RS; Qasim, A | 1 |
| Bassand, JP | 1 |
| Bittl, JA; Chaitman, BR; Feit, F; Kimball, W; Topol, EJ | 1 |
| Coste, P; Jaïs, C; Labèque, JN; Lafitte, S; Perron, JM; Roudaut, R; Zabsonré, P | 1 |
| Julian, D | 1 |
| Aylward, PE; French, JK; Gao, W; Krucoff, MW; White, HD; Wong, CK | 1 |
| Natarajan, M | 2 |
| Manda, SO | 1 |
| Breddin, HK; Esslinger, HU; Köhne, S; Radziwon, P; Walenga, JM | 1 |
| Moliterno, DJ; Saw, J | 1 |
| Bachli, EB; Meili, EO; Peter, U; Schneider, E; Schuepbach, RA | 1 |
| Brener, SJ; Lincoff, AM; Moliterno, DJ; Steinhubl, SR; Topol, EJ; Wolski, KE | 1 |
| Berger, P; Grines, C; Harrington, RA; Ohman, EM; Popma, JJ; Weitz, JI | 1 |
| Heptinstall, S; May, JA; Storey, RF | 1 |
| Horvath, M; Jilma, B; Jilma-Stohlawetz, P; Reiter, R | 1 |
| Graff, J; Harder, S | 1 |
| Bhatt, DL; Duffy, B | 1 |
| Meyer Samama, M | 1 |
| French, JK; Gao, W; Raffel, OC; Stewart, RA; White, HD; Wong, CK | 1 |
| Calatzis, A; Losonczy, H; Penz, S; Siess, W; Tóth, O | 1 |
| Daemgen-von Brevern, G; Geisen, C; Klaeffling, C; Lindhoff-Last, E; Luxembourg, B; Mani, H; Strubel, G; Toennes, SW | 1 |
| Armstrong, PW; Califf, RM; Granger, CB; Greenbaum, AB; Harrington, RA; Lokhnygina, Y; Mehta, RH; Newby, LK; Pieper, KS; Van De Werf, F | 1 |
| Henry, I; Henry, M; Hugel, M; Polydorou, A | 1 |
| Fox, SC; Heptinstall, S; White, AE; Wilcox, RG; Xavier, RG | 1 |
| Kwa, AT; Rogers, JH | 1 |
| Brodie, BR | 1 |
| Casterella, PJ; Tcheng, JE | 1 |
| Jennings, LK; Saucedo, JF | 1 |
| Schneider, DJ; Sobel, BE | 1 |
| Cohen, M; Giugliano, R; Granger, CB; Gurbel, PA; Hoekstra, J; Hollander, JE; Manoukian, SV; Pollack, CV; Saucedo, JF | 1 |
| Buerke, M; Carter, JM; Hauroeder, B; Maegdefessel, L; Michel, T; Peetz, D; Reindl, I; Schlitt, A; Schubert, S; Werdan, K | 1 |
| Bode, C; Saurbier, B; Schwarz, M | 1 |
| Bergman, G; Feldman, DN; Minutello, RM; Wong, SC | 1 |
| Gibson, CM; Hollander, JE; Pollack, CV | 1 |
| Eberli, FR; Roffi, M | 1 |
| Bett, N; Juneja, M; Ray, MJ; Walters, DL | 1 |
| Butwick, AJ; Carvalho, B | 1 |
| Wessely, R | 1 |
| Aylward, PE; Benatar, J; French, JK; Gao, W; Stewart, RA; White, HD; Wong, CK | 1 |
| Aïssaoui, N; Danchin, N | 1 |
| El-Atat, F; Jakkulla, M; Karajgikar, R; Kini, A; Kodali, V; Mares, A; Sarkar, K; Sharma, S | 1 |
| Moliterno, DJ | 1 |
| Aylward, PE; French, JK; Gao, W; Stewart, RA; White, HD; Wong, CK | 1 |
| Basra, SS; Lakkis, NM; Tsai, P | 1 |
| Ghosn, S; Sheikh-Taha, M | 1 |
| Kim, MH; Yu, LH; Zhang, HZ | 1 |
| Alberts, P; Armesto, AR; Cattaneo, M; Daray, FM; Errasti, AE; Femia, EA; Meyer, JP; Nowak, W; Podda, GM; Pugliano, M; Razzari, C; Rothlin, RP; Sakariassen, KS; Sorensen, AS | 1 |
| Bhatt, DL | 1 |
| Aslam, R; Ducrocq, N; Gerard, A; Kimmoun, A; Levy, B; Perez, P; Thivilier, C | 1 |
| Gupta, K; Singh, D; Vacek, JL | 1 |
| Byrne, RA; Kastrati, A; Laugwitz, KL; Ndrepepa, G; Neumann, FJ; Pache, J; Pöhler, A; Richardt, G; Schulz, S | 1 |
| Alexander, KP; Li, S; Magid, DJ; Peterson, ED; Roe, MT; Ting, HH; Wang, TY | 1 |
| Baber, U; Badimon, JJ; Crippa, M; Giannarelli, C; Mehran, R; Rodriguez, D; Sartori, S; Tewar, MP; Vorchheimer, DA; Zafar, MU | 1 |
| Anderson, JL; Bates, ER; Bode, C; Granger, CB; Huber, K; Kristensen, SD; Lopez Sendon, JL; Ohman, EM; Steg, PG; Tubaro, M; Valgimigli, M; Wallentin, L | 1 |
| Généreux, P; Kirtane, AJ; Madhavan, MV; Mehran, R; Stone, GW; Witzenbichler, B; Xu, K | 1 |
| Fichter, AM; Mitchell, DA; Mücke, T; Ritschl, LM; Robitzky, LK; Wagenpfeil, S; Wolff, KD | 1 |
| Cacciavillani, L; Calabrò, P; Cavallini, C; De Luca, L; De Servi, S; Gonzini, L; Leonardi, S; Mauro, C; Musumeci, G; Savonitto, S | 1 |
| Clemmensen, P; Engstrøm, T; Helqvist, S; Holmvang, L; Høfsten, DE; Jørgensen, E; Kelbæk, H; Køber, L; Laursen, PN; Møller-Helgestad, OK; Nepper-Christensen, L; Pedersen, F; Ravkilde, J; Sadjadieh, G; Saunamäki, K; Sørensen, R; Terkelsen, CJ; Tilsted, HH | 1 |
| Cavallari, I; Patti, G | 1 |
| Ivashin, DS; Olkhovsky, IA; Stolyar, MA | 1 |
| Álvarez-Antón, S; Carballeira, D; Concepción, R; Dejuán-Bitriá, C; Del Castillo, H; Delgado-Calva, FA; López-Soberón, E; Marschall, A; Martí, D; Morales, MJ; Palazuelos, J; Pérez-Guzmán, J | 1 |
| Bärnthaler, T; Buschmann, E; Heinemann, A; Mahla, E; Prüller, F; Schuligoi, R; Toth, GG | 1 |
| Bi, LJ; Jiang, W; Li, W; Song, CG; Wang, X; Yang, F; Zhao, JJ | 1 |
| Amran, FS; Becker, RC; Chan, MY; Chaudhary, VK; Chee, YL; Chen, W; Croft, G; de Kleijn, DPV; Gupta, A; Hoffman, M; Iyer, JK; Kini, RM; Koh, CY; Leong, EJE; Li, AWL; Mazlan, MIB; Monroe, DM; Richards, AM; Shih, N; Verma, V; Yap, ES; Yip, CYC | 1 |
31 review(s) available for aspirin and hirudin
| Article | Year |
|---|---|
[The future of fibrinolysis: from fibrinolytic treatment to reperfusion therapy].
Topics: Aspirin; Blood Coagulation Factors; Cholinesterase Reactivators; Chromogenic Compounds; Clinical Trials as Topic; Diacetyl; Drug Therapy, Combination; Hirudins; Humans; Infusions, Parenteral; Myocardial Infarction; Myocardial Reperfusion; Platelet Membrane Glycoproteins; Thrombin; Thrombolytic Therapy | 1992 |
[New aspects of blood coagulation inhibitory therapy within the scope of percutaneous transluminal coronary angioplasty (PTCA)].
Topics: Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Aspirin; Blood Platelets; Coronary Thrombosis; Fibrin; Heparin; Hirudin Therapy; Hirudins; Humans; Platelet Glycoprotein GPIIb-IIIa Complex; Thrombolytic Therapy | 1995 |
Thrombopoietin induces tyrosine phosphorylation of Stat3 and Stat5 in human blood platelets.
Topics: Animals; Aspirin; Blood Platelets; Cell Line; DNA-Binding Proteins; Epinephrine; Hirudins; Humans; Janus Kinase 2; Mice; Milk Proteins; Neoplasm Proteins; Phosphorylation; Platelet Aggregation; Platelet Aggregation Inhibitors; Protein Processing, Post-Translational; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Receptors, Cytokine; Receptors, Thrombopoietin; Signal Transduction; STAT1 Transcription Factor; STAT2 Transcription Factor; STAT3 Transcription Factor; STAT5 Transcription Factor; STAT6 Transcription Factor; Thrombopoietin; Trans-Activators; Transfection; Tyrosine | 1996 |
Advances in antithrombotic therapy: novel agents.
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Antithrombins; Aspirin; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Dose-Response Relationship, Drug; Double-Blind Method; Drug Design; Drug Therapy, Combination; Enzyme Activation; Factor Xa Inhibitors; Fibrinolytic Agents; Hemorrhage; Hirudin Therapy; Hirudins; Humans; Lipoproteins; Myocardial Infarction; Myocardial Ischemia; Peptide Fragments; Platelet Aggregation Inhibitors; Postoperative Complications; Protein C; Randomized Controlled Trials as Topic; Recombinant Proteins; Thrombolytic Therapy; Thrombophlebitis; Treatment Outcome | 1995 |
[Current approach in antithrombotic treatment during coronary interventions: specific thrombocyte aggregation inhibitors and direct thrombin antagonists in high-risk patients].
Topics: Adolescent; Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Antithrombins; Aspirin; Drug Therapy, Combination; Heparin; Hirudins; Humans; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIb-IX Complex; Platelet Glycoprotein GPIIb-IIIa Complex; Platelet Membrane Glycoproteins; Postoperative Complications; Receptors, Cell Surface; Risk Factors; Thrombosis | 1996 |
Evolution of improved antithrombotic and antiplatelet agents: genesis of the Comparison of Abciximab Complications with Hirulog [and back-Up Abciximab] Events Trial (CACHET).
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Antithrombins; Aspirin; Cardiac Catheterization; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Heparin; Hirudin Therapy; Hirudins; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Peptide Fragments; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Recombinant Proteins; Research Design; Ticlopidine | 1998 |
[Conservative management in patients with acute coronary syndrome].
Topics: Angina, Unstable; Anticoagulants; Aspirin; Fibrinolytic Agents; Heparin; Hirudin Therapy; Hirudins; Humans; Peptide Fragments; Recombinant Proteins | 1999 |
Anticoagulants in acute coronary syndromes.
Topics: Acute Disease; Angina, Unstable; Anticoagulants; Aspirin; Clinical Trials as Topic; Coronary Disease; Dalteparin; Enoxaparin; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Hirudin Therapy; Hirudins; Humans; Myocardial Infarction; Recombinant Proteins | 1999 |
Failed thrombolysis in myocardial infarction.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Antithrombins; Aspirin; Clinical Trials as Topic; Electrocardiography; Fibrinolytic Agents; Hirudin Therapy; Hirudins; Humans; Immunoglobulin Fab Fragments; Monitoring, Physiologic; Myocardial Infarction; Peptide Fragments; Plasminogen Activators; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prognosis; Randomized Controlled Trials as Topic; Recombinant Proteins; Recurrence; Streptokinase; Thrombolytic Therapy; Time Factors | 2000 |
Low-molecular-weight heparin and other antithrombotic agents in the setting of a fast-track revascularization in unstable coronary artery disease.
Topics: Abciximab; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Aspirin; Clinical Trials as Topic; Combined Modality Therapy; Diabetes Complications; Drug Therapy, Combination; Eptifibatide; Factor Xa Inhibitors; Heparin, Low-Molecular-Weight; Hirudin Therapy; Hirudins; Humans; Immunoglobulin Fab Fragments; Myocardial Revascularization; Oligosaccharides; Peptide Fragments; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Postoperative Complications; Randomized Controlled Trials as Topic; Recombinant Proteins; Risk Factors; Thrombocytopenia; Thrombosis; Time Factors; Tirofiban; Treatment Outcome; Tyrosine | 2000 |
[Fibrinolysis in myocardial infarction with EKG elevation. Optimization of myocardial reperfusion by treatment with antithrombotic agents].
Topics: Aspirin; Cerebral Hemorrhage; Drug Costs; Electrocardiography; Fibrinolytic Agents; Hirudin Therapy; Hirudins; Myocardial Infarction; Myocardial Reperfusion; Randomized Controlled Trials as Topic; Risk Factors; Streptokinase | 2001 |
Unstable angina.
Topics: Angina, Unstable; Aspirin; Drug Therapy, Combination; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Hirudin Therapy; Hirudins; Humans; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Ticlopidine; Treatment Outcome | 2002 |
Unstable angina.
Topics: Angina, Unstable; Aspirin; Drug Therapy, Combination; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Hirudin Therapy; Hirudins; Humans; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Ticlopidine | 2002 |
Contemporary use of antiplatelet therapies in percutaneous coronary interventions.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopidogrel; Coronary Disease; Hirudins; Humans; Immunoglobulin Fab Fragments; Peptide Fragments; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Recombinant Proteins; Stents; Ticlopidine | 2003 |
Relationship between activated clotting time and ischemic or hemorrhagic complications: analysis of 4 recent randomized clinical trials of percutaneous coronary intervention.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Aspirin; Blood Coagulation Tests; Clopidogrel; Comorbidity; Coronary Restenosis; Double-Blind Method; Drug Synergism; Drug Therapy, Combination; Female; Hemorrhage; Heparin; Hirudins; Humans; Immunoglobulin Fab Fragments; Incidence; Male; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; Myocardial Ischemia; Peptide Fragments; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Recombinant Proteins; Retrospective Studies; Stents; Thrombophilia; Ticlopidine; Tirofiban; Tyrosine | 2004 |
Antithrombotic therapy during percutaneous coronary intervention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopidogrel; Contraindications; Coronary Restenosis; Coronary Stenosis; Drug Therapy, Combination; Evidence-Based Medicine; Fibrinolytic Agents; Heparin; Hirudins; Humans; Immunoglobulin Fab Fragments; Peptide Fragments; Practice Guidelines as Topic; Pyridines; Recombinant Proteins; Risk Assessment; Stents; Ticlopidine | 2004 |
Antiplatelet agents in patients undergoing percutaneous coronary intervention: how many and how much?
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clinical Trials as Topic; Clopidogrel; Eptifibatide; Hirudins; Humans; Immunoglobulin Fab Fragments; Peptide Fragments; Peptides; Platelet Aggregation Inhibitors; Recombinant Proteins; Ticlopidine; Tirofiban; Tyrosine | 2005 |
[The new antithrombotic agents].
Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Azetidines; Benzylamines; Clopidogrel; Fibrinolytic Agents; Glycine; Hirudins; Humans; Injections, Subcutaneous; Platelet Aggregation Inhibitors; Polysaccharides; Prodrugs; Randomized Controlled Trials as Topic; Stents; Thrombosis; Ticlopidine; Time Factors; Venous Thrombosis | 2005 |
Current update on glycoprotein IIb-IIIa and direct thrombin inhibition in percutaneous coronary intervention for non-ST elevation acute coronary syndromes: balancing bleeding risk and antiplatelet efficacy.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Angiotensin-Converting Enzyme Inhibitors; Anticoagulants; Antithrombins; Aspirin; Clopidogrel; Enoxaparin; Eptifibatide; Fibrinolytic Agents; Heart Conduction System; Hemorrhage; Heparin; Hirudins; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Peptide Fragments; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Recombinant Proteins; Risk Assessment; Risk Factors; Ticlopidine | 2008 |
Review of the 2005 American College of Cardiology, American Heart Association, and Society for Cardiovascular Interventions guidelines for adjunctive pharmacologic therapy during percutaneous coronary interventions: practical implications, new clinical da
Topics: American Heart Association; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Drug-Eluting Stents; Hirudins; Humans; Peptide Fragments; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Practice Guidelines as Topic; Pyridines; Recombinant Proteins; Societies, Medical; Thrombolytic Therapy; Ticlopidine; United States | 2008 |
Antiplatelet and anticoagulant agents: key differences in mechanisms of action, clinical application, and therapeutic benefit in patients with non-ST-segment-elevation acute coronary syndromes.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Hirudins; Humans; Peptide Fragments; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Recombinant Proteins; Ticlopidine | 2008 |
Treatment strategies in non-ST-elevation acute coronary syndromes in patients undergoing percutaneous coronary intervention: an evidence-based review of clinical trial results and treatment guidelines: report on a roundtable discussion.
Topics: Acute Coronary Syndrome; Algorithms; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Cardiovascular Agents; Clinical Trials as Topic; Clopidogrel; Emergency Treatment; Evidence-Based Medicine; Fibrinolytic Agents; Hirudins; Humans; Peptide Fragments; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Postoperative Hemorrhage; Practice Guidelines as Topic; Prasugrel Hydrochloride; Recombinant Proteins; Risk Assessment; Stents; Thiophenes; Thrombosis; Ticlopidine | 2008 |
[Anticoagulant and thrombolytic agents in acute coronary syndromes].
Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Hirudins; Humans; Myocardial Infarction; Myocardial Reperfusion; Streptokinase; Thrombolytic Therapy | 2008 |
Hospitals with and without percutaneous coronary intervention capability: considerations for treating acute coronary syndromes.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Emergency Service, Hospital; Enoxaparin; Fondaparinux; Health Services Accessibility; Hirudins; Humans; Peptide Fragments; Platelet Aggregation Inhibitors; Polysaccharides; Recombinant Proteins; Ticlopidine; Triage; United States | 2009 |
Diabetes and acute coronary syndromes.
Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Blood Glucose; Clopidogrel; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Enoxaparin; Hirudins; Humans; Hypoglycemic Agents; Peptide Fragments; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Recombinant Proteins; Thiophenes; Thrombosis; Ticlopidine | 2009 |
Neuraxial anesthesia in obstetric patients receiving anticoagulant and antithrombotic drugs.
Topics: Anesthesia, Obstetrical; Anesthesia, Spinal; Anticoagulants; Aspirin; Clopidogrel; Female; Fibrinolytic Agents; Fondaparinux; Guidelines as Topic; Hematoma, Epidural, Spinal; Heparin; Hirudins; Humans; Polysaccharides; Pregnancy; Ticlopidine; Warfarin | 2010 |
Pharmacologic therapy for non ST-segment elevation acute coronary syndromes: focus on antithrombotic therapy.
Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Disease Management; Drug Synergism; Drug Therapy, Combination; Enoxaparin; Fibrinolytic Agents; Fondaparinux; Hemorrhage; Heparin; Hirudins; Humans; Peptide Fragments; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Polysaccharides; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Recombinant Proteins; Thiophenes; Ticagrelor; Ticlopidine | 2010 |
Safety and efficacy of antiplatelet and antithrombotic therapy in acute coronary syndrome patients with chronic kidney disease.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Chronic Disease; Clinical Trials as Topic; Clopidogrel; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Fibrinolytic Agents; Fondaparinux; Hemorrhage; Heparin; Hirudins; Humans; Kidney Diseases; Peptide Fragments; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Polysaccharides; Prasugrel Hydrochloride; Recombinant Proteins; Thiophenes; Ticagrelor; Ticlopidine; Uremia | 2011 |
Anticoagulation and antiplatelet therapy in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Anticoagulants; Aspirin; Benzimidazoles; beta-Alanine; Clopidogrel; Dabigatran; Enoxaparin; Fondaparinux; Heparin; Hirudins; Humans; Morpholines; Peptide Fragments; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Polysaccharides; Prasugrel Hydrochloride; Pyrazoles; Pyridones; Recombinant Proteins; Rivaroxaban; Thiophenes; Ticagrelor; Ticlopidine; Warfarin | 2014 |
Antiplatelet and anticoagulation agents in acute coronary syndromes: what is the current status and what does the future hold?
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Anticoagulants; Aspirin; Drug Therapy, Combination; Enoxaparin; Eptifibatide; Fondaparinux; Heparin; Hirudins; Humans; Lactones; Peptide Fragments; Peptides; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Polysaccharides; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Pyridines; Receptors, Thrombin; Recombinant Proteins; Thiophenes; Ticagrelor; Tirofiban; Tyrosine; Warfarin | 2014 |
Clinical effects with inhibition of multiple coagulative pathways in patients admitted for acute coronary syndrome.
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Aspirin; Blood Coagulation Factors; Fondaparinux; Hirudins; Humans; Peptide Fragments; Platelet Aggregation Inhibitors; Recombinant Proteins | 2018 |
29 trial(s) available for aspirin and hirudin
| Article | Year |
|---|---|
Hirulog in the treatment of unstable angina. Results of the Thrombin Inhibition in Myocardial Ischemia (TIMI) 7 trial.
Topics: Adult; Aged; Angina, Unstable; Aspirin; Coronary Angiography; Dose-Response Relationship, Drug; Double-Blind Method; Female; Hirudin Therapy; Hirudins; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Myocardial Revascularization; Peptide Fragments; Pilot Projects; Recombinant Proteins; Thrombin | 1995 |
Randomized double-blind comparison of two doses of Hirulog with heparin as adjunctive therapy to streptokinase to promote early patency of the infarct-related artery in acute myocardial infarction.
Topics: Aspirin; Cardiac Catheterization; Coronary Angiography; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Heparin; Hirudin Therapy; Hirudins; Humans; Infusions, Intravenous; Male; Middle Aged; Myocardial Infarction; Peptide Fragments; Recombinant Proteins; Streptokinase; Survival Rate; Thrombin; Vascular Patency | 1995 |
Initial experience with hirudin and streptokinase in acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 6 trial.
Topics: Adult; Aged; Aspirin; Female; Heparin; Hirudin Therapy; Hirudins; Humans; Infusions, Intravenous; Male; Middle Aged; Myocardial Infarction; Partial Thromboplastin Time; Pilot Projects; Streptokinase; Thrombolytic Therapy; Treatment Outcome | 1995 |
Hirudin in acute myocardial infarction. Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A Trial.
Topics: Aged; Aspirin; Double-Blind Method; Female; Hemorrhage; Heparin; Hirudin Therapy; Hirudins; Humans; Male; Middle Aged; Myocardial Infarction; Thrombin; Thrombolytic Therapy | 1994 |
A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial.
Topics: Adjuvants, Pharmaceutic; Adult; Aged; Aspirin; Coronary Angiography; Dose-Response Relationship, Drug; Female; Fibrinolytic Agents; Heparin; Hirudin Therapy; Hirudins; Humans; Male; Middle Aged; Myocardial Infarction; Partial Thromboplastin Time; Pilot Projects; Recombinant Proteins; Survival Rate; Thrombolytic Therapy; Tissue Plasminogen Activator; Treatment Outcome; Vascular Patency | 1994 |
Anticoagulant activity of Hirulog, a direct thrombin inhibitor, in humans.
Topics: Adolescent; Adult; Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Evaluation; Drug Tolerance; Hemostasis; Hirudins; Humans; Infusions, Intravenous; Male; Middle Aged; Peptide Fragments; Recombinant Proteins; Thrombin | 1993 |
Anticoagulant effects of hirulog, a novel thrombin inhibitor, in patients with coronary artery disease.
Topics: Amino Acid Sequence; Aspirin; Blood Coagulation; Blood Coagulation Tests; Cardiac Catheterization; Coronary Disease; Female; Heparin; Hirudin Therapy; Hirudins; Humans; Male; Middle Aged; Molecular Sequence Data; Peptide Fragments; Recombinant Proteins; Thrombin | 1993 |
Angiographic dose-finding study with r-hirudin (HBW 023) for the improvement of thrombolytic therapy with streptokinase (HIT-SK). Interim results.
Topics: Adult; Aged; Aspirin; Coronary Angiography; Drug Administration Routes; Drug Therapy, Combination; Female; Fibrinolytic Agents; Heparin; Hirudins; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Streptokinase | 1995 |
Randomized, double-blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO). Hirulog Early Reperfusion/Occlusion (HERO) Trial Investigators.
Topics: Analysis of Variance; Antithrombins; Aspirin; Cardiac Catheterization; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Heparin; Hirudin Therapy; Hirudins; Humans; Male; Middle Aged; Myocardial Infarction; Peptide Fragments; Recombinant Proteins; Recurrence; Streptokinase; Thrombolytic Therapy | 1997 |
Long-term oral anticoagulant therapy in patients with unstable angina or suspected non-Q-wave myocardial infarction: organization to assess strategies for ischemic syndromes (OASIS) pilot study results.
Topics: Administration, Oral; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Antithrombins; Aspirin; Coronary Artery Bypass; Electrocardiography; Hemorrhage; Hirudins; Humans; Infusions, Intravenous; Myocardial Infarction; Myocardial Ischemia; Patient Compliance; Pilot Projects; Platelet Aggregation Inhibitors; Warfarin | 1998 |
Hirudin (desirudin) and Hirulog (bivalirudin) in acute ischaemic syndromes and the rationale for the Hirulog/Early Reperfusion Occlusion (HERO-2) Study.
Topics: Aged; Antithrombins; Aspirin; Female; Fibrinolytic Agents; Heparin; Hirudin Therapy; Hirudins; Humans; Male; Middle Aged; Myocardial Infarction; Peptide Fragments; Recombinant Proteins; Streptokinase; Thrombolytic Therapy | 1998 |
The Organization to Assess Strategies for Ischemic Syndromes (OASIS) Pilot Study: evaluation of acute and long-term therapies for patients with acute coronary syndromes without ST elevation.
Topics: Acute Disease; Aged; Angina, Unstable; Anticoagulants; Aspirin; Canada; Death, Sudden, Cardiac; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Electrocardiography; Feasibility Studies; Female; Fibrinolytic Agents; Heparin; Hirudin Therapy; Hirudins; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Pilot Projects; Recombinant Proteins; Recurrence; Registries; Treatment Outcome; Warfarin | 1999 |
Design, baseline characteristics, and preliminary clinical results of the Organization to Assess Strategies for Ischemic Syndromes-2 (OASIS-2) trial.
Topics: Adult; Angina, Unstable; Anticoagulants; Aspirin; Death, Sudden, Cardiac; Double-Blind Method; Drug Administration Schedule; Female; Fibrinolytic Agents; Heparin; Hirudin Therapy; Hirudins; Humans; Male; Middle Aged; Myocardial Infarction; Recombinant Proteins; Recurrence; Risk; Treatment Outcome | 1999 |
Effects of various anticoagulant treatments on von Willebrand factor release in unstable angina.
Topics: Aged; Angina, Unstable; Anticoagulants; Antithrombins; Aspirin; Biomarkers; Blood Platelets; Dalteparin; Disease-Free Survival; Drug Administration Routes; Drug Therapy, Combination; Enoxaparin; Female; Hirudin Therapy; Hirudins; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Survival Rate; Treatment Outcome; von Willebrand Factor | 2000 |
Effects of long-term, moderate-intensity oral anticoagulation in addition to aspirin in unstable angina. The Organization to Assess Strategies for Ischemic Syndromes (OASIS) Investigators.
Topics: Administration, Oral; Adult; Aged; Angina, Unstable; Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Heparin; Hirudins; Humans; Long-Term Care; Male; Middle Aged; Myocardial Infarction; Survival Rate | 2001 |
Slowed ST segment recovery despite early infarct artery patency in patients with Q waves at presentation with a first acute myocardial infarction. Implications of initial Q waves on myocyte reperfusion.
Topics: Acute Disease; Anticoagulants; Aspirin; Coronary Angiography; Coronary Circulation; Double-Blind Method; Electrocardiography; Endpoint Determination; Female; Fibrinolytic Agents; Heparin; Hirudins; Humans; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Myocardial Reperfusion; Peptide Fragments; Predictive Value of Tests; Prospective Studies; Recombinant Proteins; Streptokinase; Thrombolytic Therapy; Vascular Patency | 2002 |
A Bayesian ordinal model for heterogeneity in a multi-centre myocardial infarction clinical trial.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Bayes Theorem; Clinical Trials, Phase I as Topic; Coronary Angiography; Female; Fibrinolytic Agents; Hirudins; Humans; Male; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; Peptide Fragments; Recombinant Proteins; Regression Analysis; Streptokinase; Treatment Outcome | 2002 |
Effects of PEG-hirudin in clotting parameters and platelet function and its interaction with aspirin in healthy volunteers.
Topics: Aspirin; Bleeding Time; Blood Coagulation; Blood Platelets; Cross-Over Studies; Hirudins; Humans; Platelet Aggregation Inhibitors; Reference Values | 2003 |
Additive effects between platelet concentrates and desmopressin in antagonizing the platelet glycoprotein IIb/IIIa inhibitor eptifibatide.
Topics: Adult; Anticoagulants; Aspirin; Blood Component Removal; Blood Platelets; Cross-Over Studies; Deamino Arginine Vasopressin; Drug Synergism; Eptifibatide; Hemostatics; Hirudins; Humans; Male; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Platelet Transfusion; Recombinant Proteins | 2005 |
Initial Q waves accompanying ST-segment elevation at presentation of acute myocardial infarction and 30-day mortality in patients given streptokinase therapy: an analysis from HERO-2.
Topics: Aged; Anticoagulants; Aspirin; Drug Therapy, Combination; Electrocardiography; Female; Heparin; Hirudins; Humans; Male; Middle Aged; Myocardial Infarction; Peptide Fragments; Predictive Value of Tests; Recombinant Proteins; Streptokinase; Thrombolytic Therapy | 2006 |
Timing of death and myocardial infarction in patients with non-ST elevation acute coronary syndromes: insights from randomized clinical trials.
Topics: Acute Disease; Aged; Angina, Unstable; Aspirin; Female; Hirudin Therapy; Hirudins; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Risk Assessment; Risk Factors; Survival; Time Factors | 2007 |
Comparison of bivalirudin, enoxaparin, and unfractionated heparin in preventing cardiac catheter thrombosis. Results of an in-vitro study.
Topics: Anticoagulants; Aspirin; Cardiac Catheterization; Enoxaparin; Eptifibatide; Erythrocytes; Fibrin; Fibrinolytic Agents; Heparin; Hirudins; Humans; In Vitro Techniques; Male; Microscopy, Electron, Scanning; Peptide Fragments; Peptides; Perfusion; Platelet Aggregation Inhibitors; Recombinant Proteins; Thrombosis | 2008 |
A comparison of anticoagulation with bivalirudin and provisional GPIIb/IIIa inhibition with unfractionated heparin and mandatory GPIIb/IIIa inhibition during percutaneous coronary intervention in relation to platelet activation and the inhibition of coagu
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Biomarkers; Blood Coagulation; CD40 Ligand; Clopidogrel; Drug Therapy, Combination; Female; Fibrinogen; Heparin; Hirudins; Humans; Lipoproteins; Male; Membrane Glycoproteins; Middle Aged; Monocytes; Peptide Fragments; Platelet Activation; Platelet Adhesiveness; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prothrombin; Recombinant Proteins; Thromboplastin; Thrombosis; Ticlopidine; Treatment Outcome | 2009 |
Prognostic value of lead V1 ST elevation during acute inferior myocardial infarction.
Topics: Aged; Anterior Wall Myocardial Infarction; Anticoagulants; Aspirin; Bundle-Branch Block; Drug Therapy, Combination; Electrocardiography; Female; Fibrinolytic Agents; Heparin; Hirudins; Humans; Male; Middle Aged; Peptide Fragments; Predictive Value of Tests; Prognosis; Recombinant Proteins; Risk Factors; Streptokinase | 2010 |
A randomized pilot trial for aggressive therapeutic approaches in aspirin-resistant patients undergoing percutaneous coronary intervention.
Topics: Adult; Angioplasty, Balloon, Coronary; Antithrombins; Aspirin; Blood Platelets; Clopidogrel; Drug Resistance; Drug Therapy, Combination; Female; Hirudins; Humans; Male; Middle Aged; Peptide Fragments; Pilot Projects; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Recombinant Proteins; Ticlopidine | 2011 |
A randomized two-by-two comparison of high-dose bolus tirofiban versus abciximab and unfractionated heparin versus bivalirudin during percutaneous coronary revascularization and stent placement: the tirofiban evaluation of novel dosing versus abciximab wi
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Antithrombins; Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; Hemorrhage; Heparin; Hirudins; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Peptide Fragments; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Recombinant Proteins; Risk Assessment; Risk Factors; Stents; Ticlopidine; Time Factors; Tirofiban; Treatment Outcome; Tyrosine; United States | 2011 |
The prognostic meaning of the full spectrum of aVR ST-segment changes in acute myocardial infarction.
Topics: Aged; Antithrombins; Aspirin; Electrocardiography; Female; Fibrinolytic Agents; Heparin; Hirudins; Humans; Male; Middle Aged; Myocardial Infarction; Peptide Fragments; Prognosis; Recombinant Proteins; Streptokinase | 2012 |
Ticagrelor reduces thrombus formation more than clopidogrel, even when co-administered with bivalirudin.
Topics: Adenosine; Adult; Antithrombins; Aspirin; Blood Coagulation; Clopidogrel; Cross-Over Studies; Drug Synergism; Female; Healthy Volunteers; Hirudins; Humans; Male; Peptide Fragments; Platelet Aggregation; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Recombinant Proteins; Thrombelastography; Ticagrelor; Ticlopidine | 2014 |
Is routine post-procedural anticoagulation warranted after primary percutaneous coronary intervention in ST-segment elevation myocardial infarction? Insights from the HORIZONS-AMI trial.
Topics: Aged; Antithrombins; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Drug Therapy, Combination; Drug-Eluting Stents; Electrocardiography; Female; Fibrinolytic Agents; Follow-Up Studies; Heparin; Hirudins; Humans; Male; Middle Aged; Peptide Fragments; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Postoperative Care; Postoperative Complications; Prospective Studies; Recombinant Proteins; Secondary Prevention; ST Elevation Myocardial Infarction; Survival Rate; Thrombolytic Therapy; Ticlopidine; Treatment Outcome | 2017 |
59 other study(ies) available for aspirin and hirudin
| Article | Year |
|---|---|
Factors responsible for ADP-induced release reaction of human platelets.
Topics: Adenosine Diphosphate; Adenosine Triphosphate; Aspirin; Citrates; Fibrinogen; gamma-Globulins; Hemophilia A; Heparin; Hirudins; Humans; Magnesium; Phenylbutazone; Phosphates; Platelet Adhesiveness; Platelet Aggregation; Serum Albumin; Sulfinpyrazone; Thrombin | 1975 |
Spontaneous platelet aggregation in arterial insufficiency: mechanisms and implications.
Topics: Adenosine; Adult; Aged; Angina Pectoris; Apyrase; Arterial Occlusive Diseases; Aspirin; Coronary Disease; Dipyridamole; Heparin; Hirudins; Humans; Ischemic Attack, Transient; Middle Aged; Myocardial Infarction; Platelet Aggregation; Prostaglandins E | 1976 |
The filtragometer: a new device for measuring platelet aggregation in venous blood of man.
Topics: Aspirin; Citrates; Coronary Disease; Female; Heparin; Hirudins; Humans; Male; Methods; Micropore Filters; Microscopy, Electron, Scanning; Platelet Aggregation; Prostaglandins E; Thromboembolism; Ultracentrifugation; Ultrafiltration; Venous Pressure | 1975 |
Aprotinin inhibits platelet adhesion to endothelial cells.
Topics: Aprotinin; Arginine; Aspirin; Cells, Cultured; Collagen; Depression, Chemical; Endothelium, Vascular; Hirudins; Humans; Infant, Newborn; Nitric Oxide; omega-N-Methylarginine; Plastics; Platelet Adhesiveness; Thrombin; Umbilical Veins | 1992 |
Effect of thrombin inhibition on the dynamics of thrombolysis and on platelet function during thrombolytic therapy.
Topics: Animals; Aspirin; Blood Platelets; Female; Heparin; Hirudins; Platelet Activation; Platelet Aggregation; Rabbits; Thrombin; Thrombolytic Therapy; Time Factors; Tissue Plasminogen Activator | 1992 |
Heparin and low molecular weight heparin but not hirudin stimulate platelet aggregation in whole blood from acetylsalicylic acid treated healthy volunteers.
Topics: Adult; Aspirin; Collagen; Dose-Response Relationship, Drug; Female; Heparin; Heparin, Low-Molecular-Weight; Hirudins; Humans; Male; Middle Aged; Oligopeptides; Platelet Aggregation; Platelet Membrane Glycoproteins; Stimulation, Chemical | 1991 |
Reocclusion after thrombolysis: a problem solved by hirudin?
Topics: Animals; Aspirin; Dose-Response Relationship, Drug; Fibrinolytic Agents; Heparin; Hirudin Therapy; Hirudins; Iliac Artery; Partial Thromboplastin Time; Rabbits; Recombinant Proteins; Recurrence; Reperfusion; Thrombolytic Therapy; Thrombosis; Tissue Plasminogen Activator | 1991 |
Antithrombotic therapy for deep arterial injury by angioplasty. Efficacy of common platelet inhibition compared with thrombin inhibition in pigs.
Topics: Angioplasty, Balloon; Animals; Arteries; Aspirin; Dipyridamole; Fibrinolytic Agents; Heart Diseases; Heparin; Hirudins; Platelet Aggregation Inhibitors; Swine; Thrombosis | 1991 |
Effects of different hirudins and combinations of low doses of hirudin, heparin and acetylsalicylic acid in a rat microcirculatory thrombosis model.
Topics: Animals; Aspirin; Drug Combinations; Drug Synergism; Fibrinolytic Agents; Heparin; Hirudin Therapy; Hirudins; Lasers; Male; Mesenteric Veins; Rats; Rats, Inbred Strains; Recombinant Proteins; Thrombolytic Therapy; Thrombosis | 1991 |
Relative efficacy of antithrombin compared with antiplatelet agents in accelerating coronary thrombolysis and preventing early reocclusion.
Topics: Animals; Aspirin; Coronary Thrombosis; Dogs; Fibrinolytic Agents; Heparin; Hirudin Therapy; Hirudins; Platelet Aggregation Inhibitors; Platelet Membrane Glycoproteins; Recombinant Proteins; Recurrence; Thrombin; Thrombolytic Therapy; Tissue Plasminogen Activator | 1991 |
[Thrombin as a common target of action for antithrombotic drugs in vivo].
Topics: Aspirin; Drugs, Chinese Herbal; Female; Fibrinolytic Agents; Glycosaminoglycans; Heparin; Hirudins; Humans; Male; Thrombin; Warfarin | 1990 |
Interleukin 1 stimulates platelet-activating factor production in cultured human endothelial cells.
Topics: Acetyl Coenzyme A; Acetyl-CoA C-Acetyltransferase; Aspirin; Cells, Cultured; Chromatography, High Pressure Liquid; Cycloheximide; Dose-Response Relationship, Drug; Endothelium; Hirudins; Humans; Interleukin-1; Lipopolysaccharides; Platelet Activating Factor | 1986 |
A method of testing platelet aggregation in native whole blood.
Topics: Adult; Aspirin; Blood; Collagen; Electric Conductivity; Female; Heparin; Hirudins; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Function Tests; Thiourea | 1985 |
Characterization of the platelet-aggregating activity of tumor cells.
Topics: Adenocarcinoma; Adenosine Diphosphate; Animals; Aspirin; Cell Line; Cell Membrane; Growth Substances; Hirudins; In Vitro Techniques; Kidney Neoplasms; Magnesium; Mice; Neoplasms, Experimental; Neuroblastoma; Platelet Aggregation; Rabbits | 1980 |
Thrombin-receptor agonist peptides, in contrast to thrombin itself, are not full agonists for activation and signal transduction in human platelets in the absence of platelet-derived secondary mediators.
Topics: Adenosine Diphosphate; Amino Acid Sequence; Arachidonic Acid; Aspirin; Blood Platelets; Cytoskeleton; Drug Interactions; GTP-Binding Proteins; Hirudins; Humans; Integrin alpha2; Membrane Glycoproteins; Molecular Sequence Data; Phosphatidylinositols; Phospholipases A; Phospholipases A2; Phosphorylation; Platelet Activation; Platelet Aggregation; Proto-Oncogene Proteins pp60(c-src); Purinergic P2 Receptor Antagonists; Receptors, Thrombin; Signal Transduction; Thrombin | 1994 |
Macroaggregation of platelets in plasma, as distinct from microaggregation in whole blood (and plasma), as determined using optical aggregometry and platelet counting respectively, is specifically impaired following cardiopulmonary bypass in man.
Topics: Aprotinin; Aspirin; Blood; Blood Loss, Surgical; Cardiopulmonary Bypass; Collagen; Hirudins; Humans; Nephelometry and Turbidimetry; Plasma; Platelet Activation; Platelet Aggregation; Platelet Count; Platelet Function Tests; Recombinant Proteins; Ristocetin | 1994 |
Platelet and fibrin deposition on coronary stents in minipigs: effect of hirudin versus heparin.
Topics: Angioplasty, Balloon, Coronary; Animals; Aspirin; Coronary Thrombosis; Dextrans; Drug Evaluation, Preclinical; Drug Therapy, Combination; Female; Fibrin; Heparin; Hirudin Therapy; Hirudins; Indium Radioisotopes; Male; Platelet Aggregation; Recombinant Proteins; Stents; Swine; Swine, Miniature; Time Factors | 1993 |
Inhibition of platelet deposition by combined hirulog and aspirin in a rat carotid endarterectomy model.
Topics: Animals; Aspirin; Blood Platelets; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy, Combination; Endarterectomy, Carotid; Hirudin Therapy; Hirudins; Male; Peptide Fragments; Postoperative Complications; Random Allocation; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Thrombin; Thrombosis | 1995 |
Purification and characterization of L-amino acid oxidase from king cobra (Ophiophagus hannah) venom and its effects on human platelet aggregation.
Topics: Alprostadil; Amino Acid Oxidoreductases; Animals; Antimycin A; Aspirin; Blood Coagulation Tests; Blood Platelets; Catalase; Chromatography, Gel; Chromatography, Ion Exchange; Drug Interactions; Edetic Acid; Elapid Venoms; Electrophoresis, Polyacrylamide Gel; Heparin; Hirudins; Humans; Hydrogen Peroxide; Indomethacin; Isoelectric Point; L-Amino Acid Oxidase; Molecular Weight; Nitroprusside; Platelet Aggregation; Quinacrine; Thromboxane A2; Verapamil | 1994 |
Ca2+ influx in platelets: activation by thrombin and by the depletion of the stores. Effect of cyclic nucleotides.
Topics: Aspirin; Biological Transport, Active; Blood Platelets; Calcium; Calcium-Transporting ATPases; Drug Interactions; Egtazic Acid; Epoprostenol; Hirudins; Humans; Ionomycin; Manganese; Nitroprusside; Nucleotides, Cyclic; Platelet Activation; Terpenes; Thapsigargin; Thrombin | 1994 |
Prevention of intra-coronary thrombosis in the anaesthetised dog: the importance of thromboxane A2 and thrombin.
Topics: Anesthesia; Animals; Aspirin; Biphenyl Compounds; Blood Coagulation Tests; Coronary Circulation; Coronary Thrombosis; Dogs; Drug Synergism; Drug Therapy, Combination; Electric Stimulation; Female; Fibrinolytic Agents; Heptanoic Acids; Hirudin Therapy; Hirudins; Male; Platelet Aggregation; Recombinant Proteins; Thrombin; Thromboxane A2; Ticlopidine | 1994 |
Collagen induced human platelet aggregation: serotonin receptor antagonism retards aggregate growth in vitro.
Topics: Apyrase; Aspirin; Blood Platelets; Collagen; Epinephrine; Hirudins; Humans; In Vitro Techniques; Platelet Aggregation; Platelet Count; Quinolines; Recombinant Proteins; Serotonin; Serotonin Antagonists | 1993 |
Experimental thrombosis on a collagen coated arterioarterial shunt in rats: a pharmacological model to study antithrombotic agents inhibiting thrombin formation and platelet deposition.
Topics: Animals; Anticoagulants; Arterio-Arterial Fistula; Aspirin; Carotid Artery Thrombosis; Clopidogrel; Collagen; Disease Models, Animal; Drug Evaluation, Preclinical; Fibrin; Fibrinogen; Fibrinolytic Agents; Glass; Heparin; Hirudin Therapy; Hirudins; Male; Platelet Adhesiveness; Platelet Aggregation Inhibitors; Polyethylenes; Rats; Rats, Wistar; Recombinant Proteins; Regional Blood Flow; Silicones; Thrombin; Ticlopidine | 1993 |
Maintenance of patency after thrombolysis in stenotic coronary arteries requires combined inhibition of thrombin and platelets.
Topics: Animals; Aspirin; Blood Platelets; Coronary Disease; Dogs; Drug Therapy, Combination; Hirudin Therapy; Hirudins; Male; Recurrence; Thrombin; Thrombolytic Therapy; Tissue Plasminogen Activator; Vascular Patency | 1993 |
Does antithrombotic therapy influence residual thrombus after thrombolysis of platelet-rich thrombus? Effects of recombinant hirudin, heparin, or aspirin.
Topics: Animals; Aspirin; Blood Platelets; Carotid Arteries; Drug Therapy, Combination; Fibrin; Fibrinolytic Agents; Hemostasis; Heparin; Hirudin Therapy; Hirudins; Humans; Recombinant Proteins; Swine; Thrombosis; Time Factors; Tissue Plasminogen Activator | 1996 |
Magnesium inhibits human platelets.
Topics: Aspirin; Blood Platelets; Collagen; Female; Hirudins; Humans; In Vitro Techniques; Magnesium; Magnesium Sulfate; Male; Platelet Aggregation; Thromboxane A2; Thromboxane B2 | 1996 |
Comparison of enoxaparin, hirulog, and heparin as adjunctive antithrombotic therapy during thrombolysis with rtPA in the stenosed canine coronary artery.
Topics: Adenosine Diphosphate; Animals; Aspirin; Bleeding Time; Collagen; Coronary Thrombosis; Dogs; Drug Evaluation, Preclinical; Drug Synergism; Drug Therapy, Combination; Enoxaparin; Factor Xa Inhibitors; Female; Fibrinolytic Agents; Hemorrhage; Hemostasis; Heparin; Hirudin Therapy; Hirudins; Male; Partial Thromboplastin Time; Peptide Fragments; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Count; Prothrombin; Prothrombin Time; Recombinant Proteins; Recurrence; Safety; Thrombin; Thrombolytic Therapy; Tissue Plasminogen Activator | 1997 |
Dissolution of mural thrombus by specific thrombin inhibition with r-hirudin: comparison with heparin and aspirin.
Topics: Animals; Aspirin; Drug Evaluation, Preclinical; Drug Synergism; Drug Therapy, Combination; Fibrinolytic Agents; Heart Diseases; Hematocrit; Heparin; Hirudin Therapy; Hirudins; Partial Thromboplastin Time; Platelet Aggregation Inhibitors; Platelet Count; Recombinant Proteins; Swine; Thrombin; Thrombolytic Therapy; Thrombosis | 1998 |
Development of an anti-bleeding agent for recombinant hirudin induced skin bleeding in the pig.
Topics: Animals; Aspirin; Bleeding Time; Factor VIII; Hemorrhage; Hirudins; Infusions, Intravenous; Male; Platelet Aggregation Inhibitors; Protein Engineering; Recombinant Proteins; Skin; Swine; von Willebrand Factor | 1998 |
Differential effects of three radiographic contrast media on platelet aggregation and degranulation: implications for clinical practice?
Topics: Adenosine Diphosphate; Antithrombins; Aspirin; Cell Degranulation; Contrast Media; Hirudins; Humans; Iopamidol; Ioxaglic Acid; P-Selectin; Platelet Aggregation; Platelet Aggregation Inhibitors; Triiodobenzoic Acids | 1998 |
Demonstration of flow and platelet dependency in a ferric chloride-induced model of thrombosis.
Topics: Animals; Antifibrinolytic Agents; Antithrombins; Arterial Occlusive Diseases; Aspirin; Blood Platelets; Carotid Artery Diseases; Carotid Artery, Common; Chlorides; Ferric Compounds; Fibrinolytic Agents; Heparin; Hirudins; Immune Sera; Ligation; Male; Platelet Aggregation; Platelet Aggregation Inhibitors; Rats; Rats, Sprague-Dawley; Regional Blood Flow; Thrombosis; Tranexamic Acid | 1999 |
Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: Final report reanalysis of the Bivalirudin Angioplasty Study.
Topics: Actuarial Analysis; Adult; Aged; Aged, 80 and over; Angina Pectoris; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Female; Follow-Up Studies; Heparin; Hirudin Therapy; Hirudins; Humans; Logistic Models; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Peptide Fragments; Randomized Controlled Trials as Topic; Recombinant Proteins; Survival Rate | 2001 |
Absolute and relative truth in clinical trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Heparin; Hirudin Therapy; Hirudins; Humans; Myocardial Infarction; Peptide Fragments; Randomized Controlled Trials as Topic; Recombinant Proteins; Reproducibility of Results | 2002 |
Lepirudin therapy for thrombotic complications in congenital afibrinogenaemia.
Topics: Afibrinogenemia; Aspirin; Blood Coagulation Tests; Drug Therapy, Combination; Heparin; Hirudins; Humans; Infant, Newborn; Male; Recombinant Proteins; Recurrence; Thrombosis | 2004 |
Potentiation of platelet aggregation by heparin in human whole blood is attenuated by P2Y12 and P2Y1 antagonists but not aspirin.
Topics: Adenosine Diphosphate; Adenosine Monophosphate; Aspirin; Blood Platelets; Cell Degranulation; Dalteparin; Drug Synergism; Heparin; Hirudins; Humans; In Vitro Techniques; Membrane Proteins; Platelet Aggregation; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y1; Receptors, Purinergic P2Y12 | 2005 |
Investigation of the PADA as a method for monitoring GPIIb/IIIa inhibitors and other antiplatelet agents.
Topics: Abciximab; Adenosine Monophosphate; Antibodies, Monoclonal; Anticoagulants; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Drug Monitoring; Eptifibatide; Hirudins; Humans; Immunoglobulin Fab Fragments; Peptides; Platelet Adhesiveness; Platelet Aggregation Inhibitors; Platelet Function Tests; Platelet Glycoprotein GPIIb-IIIa Complex; Sensitivity and Specificity; Ticlopidine | 2005 |
Multiple electrode aggregometry: a new device to measure platelet aggregation in whole blood.
Topics: Adenosine Diphosphate; Anticoagulants; Apyrase; Aspirin; Blood Preservation; Citrates; Collagen; Dose-Response Relationship, Drug; Electric Impedance; Electrodes; Hirudins; Humans; In Vitro Techniques; Peptide Fragments; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Count; Platelet Function Tests; Reference Values; Reproducibility of Results; Sensitivity and Specificity; Sodium Citrate; Time Factors | 2006 |
Factitious anticoagulant-resistance as a cause of recurrent arterial bypass graft occlusions.
Topics: Anticoagulants; Arterial Occlusive Diseases; Aspirin; Clopidogrel; Drug Resistance; Drug Therapy, Combination; Factitious Disorders; Female; Graft Occlusion, Vascular; Heparin, Low-Molecular-Weight; Hirudins; Humans; Iliac Artery; Middle Aged; Munchausen Syndrome; Phenprocoumon; Platelet Aggregation Inhibitors; Recombinant Proteins; Recurrence; Reoperation; Ticlopidine; Treatment Refusal; Vascular Surgical Procedures | 2007 |
Endovascular treatment of a renal artery stenosis: techniques, indications, results. Role of embolic protection devices (part 2).
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Catheterization; Clopidogrel; Embolism; Fibrinolytic Agents; Heparin; Hirudins; Humans; Peptide Fragments; Platelet Aggregation Inhibitors; Recombinant Proteins; Renal Artery Obstruction; Ticlopidine | 2007 |
Enhanced platelet aggregation and activation under conditions of hypothermia.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Adenosine Diphosphate; Adenosine Monophosphate; Anticoagulants; Antigens, CD; Aspirin; Blood Platelets; Blood Specimen Collection; Citrates; Cold Temperature; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Hirudins; Humans; Hypothermia, Induced; In Vitro Techniques; P-Selectin; Platelet Activating Factor; Platelet Activation; Platelet Aggregation; Platelet Function Tests; Platelet Membrane Glycoproteins; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Receptors, Thrombin; Tetraspanin 30; Time Factors | 2007 |
What anti-thrombotic therapy is best with primary PCI for acute ST elevation myocardial infarction: how should the HORIZONS trial change current practice?
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Cardiovascular Diseases; Clopidogrel; Fibrinolytic Agents; Hemorrhage; Heparin; Hirudins; Humans; Myocardial Infarction; Patient Selection; Peptide Fragments; Platelet Glycoprotein GPIIb-IIIa Complex; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Recombinant Proteins; Research Design; Stents; Thrombin; Thrombosis; Ticlopidine; Treatment Outcome | 2008 |
Lack of early augmentation of platelet reactivity after coronary intervention in patients treated with bivalirudin.
Topics: Adenosine Diphosphate; Angina Pectoris; Anticoagulants; Aspirin; Cardiac Catheterization; Clopidogrel; Elective Surgical Procedures; Hemostatics; Hirudins; Humans; Peptide Fragments; Platelet Activation; Platelet Aggregation Inhibitors; Postoperative Period; Recombinant Proteins; Thrombin; Ticlopidine; Time Factors | 2009 |
Frequency and outcomes of provisional glycoprotein IIb/IIIa blockade in patients receiving bivalirudin during percutaneous coronary intervention.
Topics: Abciximab; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Aspirin; Clopidogrel; Drug Therapy, Combination; Embolism; Eptifibatide; Female; Follow-Up Studies; Hirudins; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Peptide Fragments; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Recombinant Proteins; Registries; Regression Analysis; Retrospective Studies; Thrombosis; Ticlopidine; Treatment Outcome | 2009 |
Initial experience with an institutional bridging protocol for patients with recent coronary stent implantation requiring discontinuation of dual antiplatelet therapy resulting from urgent surgery.
Topics: Antithrombins; Aspirin; Blood Loss, Surgical; Clopidogrel; Coronary Thrombosis; Drug-Eluting Stents; Hirudins; Humans; Peptide Fragments; Platelet Aggregation Inhibitors; Postoperative Hemorrhage; Recombinant Proteins; Stents; Surgical Procedures, Operative; Ticlopidine; Time Factors | 2011 |
Comparison of bolus only with bolus plus infusion of bivalirudin in patients undergoing elective percutaneous coronary intervention: a retrospective observational study.
Topics: Aged; Alabama; Antithrombins; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Elective Surgical Procedures; Female; Hemorrhage; Hirudins; Humans; Incidence; Infusions, Intravenous; Injections, Intravenous; Ischemia; Male; Middle Aged; Peptide Fragments; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Recombinant Proteins; Retrospective Studies; Severity of Illness Index; Thrombosis; Ticlopidine | 2012 |
Effect of different anticoagulants on multiple electrode platelet aggregometry after clopidogrel and aspirin administration in patients undergoing coronary stent implantation: a comparison between citrate and hirudin.
Topics: Adenosine Diphosphate; Aged; Analysis of Variance; Angioplasty, Balloon, Coronary; Anticoagulants; Arachidonic Acid; Aspirin; Citric Acid; Clopidogrel; Female; Hirudins; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Risk Factors; ROC Curve; Sensitivity and Specificity; Stents; Ticlopidine | 2013 |
EV-077 in vitro inhibits platelet aggregation in type-2 diabetics on aspirin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Arachidonic Acid; Aspirin; Coronary Artery Disease; Diabetes Mellitus, Type 2; Dinoprostone; Female; Hirudins; Humans; Isoprostanes; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Umbilical Arteries; Vascular Resistance | 2012 |
Bleeding complications during percutaneous coronary intervention.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Aspirin; Clopidogrel; Hemorrhage; Heparin; Heparin, Low-Molecular-Weight; Hirudins; Humans; Immunoglobulin Fab Fragments; Peptide Fragments; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Recombinant Proteins; Ticlopidine | 2004 |
Critical illness-related corticosteroid insufficiency in cardiogenic shock.
Topics: Adrenal Insufficiency; Adrenergic alpha-Agonists; Adult; Anti-Inflammatory Agents; Antihypertensive Agents; Aspirin; Bisoprolol; Critical Illness; Epinephrine; Fibrinolytic Agents; Hirudins; Humans; Hydrocortisone; Male; Peptide Fragments; Piperazines; Prasugrel Hydrochloride; Ramipril; Recombinant Proteins; Shock, Cardiogenic; Thiophenes; Treatment Outcome | 2013 |
Prognostic value of bleeding after percutaneous coronary intervention in patients with diabetes.
Topics: Abciximab; Aged; Antibodies, Monoclonal; Anticoagulants; Antithrombins; Aspirin; Clopidogrel; Coronary Artery Disease; Diabetes Mellitus, Type 2; Female; Hemorrhage; Heparin; Hirudins; Humans; Immunoglobulin Fab Fragments; Logistic Models; Male; Middle Aged; Peptide Fragments; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prognosis; Proportional Hazards Models; Recombinant Proteins; Risk Factors; Stents; Ticlopidine | 2014 |
The quality of antiplatelet and anticoagulant medication administration among ST-segment elevation myocardial infarction patients transferred for primary percutaneous coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Cohort Studies; Early Medical Intervention; Female; Guideline Adherence; Heparin; Heparin, Low-Molecular-Weight; Hirudins; Humans; Male; Middle Aged; Myocardial Infarction; Patient Transfer; Peptide Fragments; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Practice Guidelines as Topic; Pyridines; Recombinant Proteins; Retrospective Studies; Ticlopidine; Time-to-Treatment | 2014 |
Impact of different antithrombotics on the microcirculation and viability of perforator-based ischaemic skin flaps in a small animal model.
Topics: Animals; Aspirin; Clopidogrel; Disease Models, Animal; Fibrinolytic Agents; Graft Survival; Heparin; Hirudins; Ischemia; Laser-Doppler Flowmetry; Male; Microcirculation; Pentoxifylline; Postoperative Complications; Rats; Rats, Wistar; Skin Diseases; Skin Transplantation; Surgical Flaps; Ticlopidine | 2016 |
Antithrombotic strategies in the catheterization laboratory for patients with acute coronary syndromes undergoing percutaneous coronary interventions: insights from the EmploYEd antithrombotic therapies in patients with acute coronary Syndromes HOspitaliz
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Cross-Sectional Studies; Female; Heparin; Hirudins; Humans; Italy; Logistic Models; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Peptide Fragments; Percutaneous Coronary Intervention; Platelet Glycoprotein GPIIb-IIIa Complex; Prospective Studies; Recombinant Proteins; Registries | 2017 |
Relation of Bleeding Events to Mortality in Patients With ST-Segment Elevation Myocardial Infarction Treated by Percutaneous Coronary Intervention (a DANAMI-3 Substudy).
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Aspirin; Creatinine; Female; Heparin; Hirudins; Humans; Incidence; Male; Middle Aged; Mortality; Multivariate Analysis; Peptide Fragments; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Postoperative Hemorrhage; Prognosis; Proportional Hazards Models; Purinergic P2Y Receptor Antagonists; Recombinant Proteins; Sex Factors; ST Elevation Myocardial Infarction; Time-to-Treatment | 2018 |
[ON THE ISSUE OF SELECTION OF COAGULANTS UNDER ADP-INDUCED IMPEDANCE TEST OF AGGREGATION OF THROMBOCYTES IN PATIENTS WITH CHRONIC MYELO-PROLIFERATIVE TUMORS].
Topics: Adenosine Triphosphate; Adult; Aged; Anticoagulants; Aspirin; Blood Platelets; Citrates; Electric Impedance; Female; Healthy Volunteers; Heparin; Hirudins; Humans; Male; Middle Aged; Myeloproliferative Disorders; Platelet Activating Factor; Platelet Aggregation | 2017 |
Impact of Anemia on the Risk of Bleeding Following Percutaneous Coronary Interventions in Patients ≥75 Years of Age.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Anemia; Angina, Unstable; Anticoagulants; Antithrombins; Aspirin; Cause of Death; Clopidogrel; Comorbidity; Coronary Artery Disease; Drug-Eluting Stents; Female; Gastrointestinal Hemorrhage; Hemorrhage; Heparin; Hirudins; Humans; Intracranial Hemorrhages; Kaplan-Meier Estimate; Male; Myocardial Infarction; Peptide Fragments; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Postoperative Care; Postoperative Hemorrhage; Prasugrel Hydrochloride; Proportional Hazards Models; Prospective Studies; Recombinant Proteins; Risk Assessment; Stents; Ticagrelor; Urologic Diseases | 2020 |
Supplemental Fibrinogen Restores Platelet Inhibitor-Induced Reduction in Thrombus Formation without Altering Platelet Function: An In Vitro Study.
Topics: Aged; Aspirin; Calcium Signaling; Female; Fibrinogen; Hemorheology; Heparin; Hirudins; Humans; In Vitro Techniques; Male; Middle Aged; P-Selectin; Platelet Activation; Platelet Aggregation Inhibitors; Thrombosis; Ticagrelor; Tirofiban | 2020 |
The efficacy and safety of Hirudin plus Aspirin versus Warfarin in the secondary prevention of Cardioembolic Stroke due to Nonvalvular Atrial Fibrillation: A multicenter prospective cohort study.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Embolic Stroke; Female; Follow-Up Studies; Hirudins; Humans; Male; Middle Aged; Prospective Studies; Recurrence; Secondary Prevention; Treatment Outcome; Warfarin | 2021 |
Efficacy and safety of next-generation tick transcriptome-derived direct thrombin inhibitors.
Topics: Amblyomma; Animals; Antibodies; Anticoagulants; Antidotes; Antithrombins; Aspirin; Drug Development; Drug Discovery; Female; Fibrinolytic Agents; Gene Library; Heparin; Hirudins; Humans; Male; Peptide Fragments; Percutaneous Coronary Intervention; Proteomics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Swine; Thrombin; Thrombosis; Ticks; Transcriptome | 2021 |